According to the 2019 WHO classification of tumors, CK19-positive HCC displays significantly greater resistance to conventional transarterial chemoembolization (cTACE), with evidence suggesting that CK19-positive HCC patients exhibit poorer treatment responses to cTACE [11]. This evidence concerns the gene KRT19 and hepatocellular carcinoma.